These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

293 related articles for article (PubMed ID: 31382120)

  • 1. Novel dual inhibitors targeting CDK4 and VEGFR2 synergistically suppressed cancer progression and angiogenesis.
    Huang Z; Zhao B; Qin Z; Li Y; Wang T; Zhou W; Zheng J; Yang S; Shi Y; Fan Y; Xiang R
    Eur J Med Chem; 2019 Nov; 181():111541. PubMed ID: 31382120
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Oleanolic Acid Inhibits Colorectal Cancer Angiogenesis by Blocking the VEGFR2 Signaling Pathway.
    Niu G; Sun L; Pei Y; Wang D
    Anticancer Agents Med Chem; 2018; 18(4):583-590. PubMed ID: 29065844
    [TBL] [Abstract][Full Text] [Related]  

  • 3. JHD205, A Novel Abemaciclib Derivative, Exerts Antitumor Effects on Breast Cancer by CDK4/6.
    Ji J; Qin J; Wang X; Lv M; Hou X; Jing A; Zhou J; Zuo L; Liu W; Feng J; Qian Q; Liu Y; Wang X; Liu B
    Anticancer Agents Med Chem; 2024; 24(6):400-411. PubMed ID: 38192142
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Structure-based design, synthesis, and evaluation of imidazo[1,2-b]pyridazine and imidazo[1,2-a]pyridine derivatives as novel dual c-Met and VEGFR2 kinase inhibitors.
    Matsumoto S; Miyamoto N; Hirayama T; Oki H; Okada K; Tawada M; Iwata H; Nakamura K; Yamasaki S; Miki H; Hori A; Imamura S
    Bioorg Med Chem; 2013 Dec; 21(24):7686-98. PubMed ID: 24216091
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Design, synthesis, and evaluation of novel VEGFR2 kinase inhibitors: discovery of [1,2,4]triazolo[1,5-a]pyridine derivatives with slow dissociation kinetics.
    Oguro Y; Cary DR; Miyamoto N; Tawada M; Iwata H; Miki H; Hori A; Imamura S
    Bioorg Med Chem; 2013 Aug; 21(15):4714-29. PubMed ID: 23755884
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Altiratinib Inhibits Tumor Growth, Invasion, Angiogenesis, and Microenvironment-Mediated Drug Resistance via Balanced Inhibition of MET, TIE2, and VEGFR2.
    Smith BD; Kaufman MD; Leary CB; Turner BA; Wise SC; Ahn YM; Booth RJ; Caldwell TM; Ensinger CL; Hood MM; Lu WP; Patt TW; Patt WC; Rutkoski TJ; Samarakoon T; Telikepalli H; Vogeti L; Vogeti S; Yates KM; Chun L; Stewart LJ; Clare M; Flynn DL
    Mol Cancer Ther; 2015 Sep; 14(9):2023-34. PubMed ID: 26285778
    [TBL] [Abstract][Full Text] [Related]  

  • 7. PBA2 exhibits potent anti-tumor activity via suppression of VEGFR2 mediated-cell proliferation and angiogenesis.
    Fang X; Xie H; Luo M; Chen Z; Wang F; Li Q; Wang X; Ding J; Fu L
    Biochem Pharmacol; 2018 Apr; 150():131-140. PubMed ID: 29408327
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Salinomycin exerts anti-angiogenic and anti-tumorigenic activities by inhibiting vascular endothelial growth factor receptor 2-mediated angiogenesis.
    Li T; Liu X; Shen Q; Yang W; Huo Z; Liu Q; Jiao H; Chen J
    Oncotarget; 2016 May; 7(18):26580-92. PubMed ID: 27058891
    [TBL] [Abstract][Full Text] [Related]  

  • 9. SKLB610: a novel potential inhibitor of vascular endothelial growth factor receptor tyrosine kinases inhibits angiogenesis and tumor growth in vivo.
    Cao ZX; Zheng RL; Lin HJ; Luo SD; Zhou Y; Xu YZ; Zeng XX; Wang Z; Zhou LN; Mao YQ; Yang L; Wei YQ; Yu LT; Yang SY; Zhao YL
    Cell Physiol Biochem; 2011; 27(5):565-74. PubMed ID: 21691074
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A novel 2-aminobenzimidazole-based compound Jzu 17 exhibits anti-angiogenesis effects by targeting VEGFR-2 signalling.
    Lien JC; Chung CL; Huang TF; Chang TC; Chen KC; Gao GY; Hsu MJ; Huang SW
    Br J Pharmacol; 2019 Oct; 176(20):4034-4049. PubMed ID: 31368127
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Discovery of a novel series of imidazo[1',2':1,6]pyrido[2,3-d]pyrimidin derivatives as potent cyclin-dependent kinase 4/6 inhibitors.
    Shi C; Wang Q; Liao X; Ge H; Huo G; Zhang L; Chen N; Zhai X; Hong Y; Wang L; Wang Z; Shi W; Mao Y; Yu J; Ke Y; Xia G
    Eur J Med Chem; 2020 May; 193():112239. PubMed ID: 32200202
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Design, synthesis and in┬ávitro evaluation of 6-amide-2-aryl benzoxazole/benzimidazole derivatives against tumor cells by inhibiting VEGFR-2 kinase.
    Yuan X; Yang Q; Liu T; Li K; Liu Y; Zhu C; Zhang Z; Li L; Zhang C; Xie M; Lin J; Zhang J; Jin Y
    Eur J Med Chem; 2019 Oct; 179():147-165. PubMed ID: 31252306
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Antiangiogenic mechanisms of PJ-8, a novel inhibitor of vascular endothelial growth factor receptor signaling.
    Huang SW; Lien JC; Kuo SC; Huang TF
    Carcinogenesis; 2012 May; 33(5):1022-30. PubMed ID: 22436611
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Double-edged Swords: Diaryl pyrazoline thiazolidinediones synchronously targeting cancer epigenetics and angiogenesis.
    Upadhyay N; Tilekar K; Safuan S; Kumar AP; Schweipert M; Meyer-Almes FJ; Ramaa CS
    Bioorg Chem; 2021 Nov; 116():105350. PubMed ID: 34547645
    [TBL] [Abstract][Full Text] [Related]  

  • 15. DCLAK11, a multi-tyrosine kinase inhibitor, exhibits potent antitumor and antiangiogenic activity in vitro.
    Guo XB; Chen XJ; Tong LJ; Peng X; Huang M; Liu HC; Liu H; Ding J
    Acta Pharmacol Sin; 2015 Oct; 36(10):1266-76. PubMed ID: 26027659
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Inhibition of tumor cell growth and angiogenesis by 7-aminoalkoxy-4-aryloxy-quinazoline ureas, a novel series of multi-tyrosine kinase inhibitors.
    Ravez S; Barczyk A; Six P; Cagnon A; Garofalo A; Goossens L; Depreux P
    Eur J Med Chem; 2014 May; 79():369-81. PubMed ID: 24747748
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Exploration of carbamide derived pyrimidine-thioindole conjugates as potential VEGFR-2 inhibitors with anti-angiogenesis effect.
    Sana S; Reddy VG; Bhandari S; Reddy TS; Tokala R; Sakla AP; Bhargava SK; Shankaraiah N
    Eur J Med Chem; 2020 Aug; 200():112457. PubMed ID: 32422489
    [TBL] [Abstract][Full Text] [Related]  

  • 18. YM-359445, an orally bioavailable vascular endothelial growth factor receptor-2 tyrosine kinase inhibitor, has highly potent antitumor activity against established tumors.
    Amino N; Ideyama Y; Yamano M; Kuromitsu S; Tajinda K; Samizu K; Hisamichi H; Matsuhisa A; Shirasuna K; Kudoh M; Shibasaki M
    Clin Cancer Res; 2006 Mar; 12(5):1630-8. PubMed ID: 16533791
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Chitosan sulfate inhibits angiogenesis via blocking the VEGF/VEGFR2 pathway and suppresses tumor growth in vivo.
    Li Y; Wang W; Zhang Y; Wang X; Gao X; Yuan Z; Li Y
    Biomater Sci; 2019 Mar; 7(4):1584-1597. PubMed ID: 30694269
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Design, synthesis, and biological evaluation of 4,5-dihydro-[1,2,4]triazolo[4,3-f]pteridine derivatives as novel dual-PLK1/BRD4 inhibitors.
    Wang NY; Xu Y; Xiao KJ; Zuo WQ; Zhu YX; Hu R; Wang WL; Shi YJ; Yu LT; Liu ZH
    Eur J Med Chem; 2020 Apr; 191():112152. PubMed ID: 32088495
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.